Fusion Pharmaceuticals
based tat provides enhanced tumor specificity | Fusion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
20 of 33
Related slides by other companies
Alkermes
Investor Day
March 2021
oncology goal activate innate and adaptive immune responses to drive tumor cell death enhanced antigen identification and presentation cell death amplified immune system activation enhanced immune cell mediated tumor cell death chemotherapy radiation inhibitors targeted agents growth factor inhibitors dendritic cell presenting antigen activation and expansion cells and cells activated cells attacking tumor tumor killing and release of antigens cells cells | Alkermes
Other recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
June 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights